Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
143
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B-cell non-Hodgkin lymphoma

Aliza Gardenswartza Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Brinda Mehtab Department of Pediatrics, St. Jude Children’s Research Hospital, Peoria, IL, USAView further author information
,
Nader Kim El-Mallawanyc Department of Pediatrics, Baylor College of Medicine, Houston, TX, USAView further author information
,
Carmella van de Vena Department of Pediatrics, New York Medical College, Valhalla, NY, USAORCID Iconhttps://orcid.org/0000-0001-7919-1089View further author information
ORCID Icon,
Jessica Hochberga Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Allyson Flowerd Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USAView further author information
,
Erin Morrisa Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Lauren Harrisona Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Yaya Chua Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Jaclyn Bassoa Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Perry Gerarde Department of Radiology, New York Medical College, Valhalla, NY, USAView further author information
,
Humayun Islamf Department of Pathology, New York Medical College, Valhalla, NY, USAView further author information
,
Janet Ayelloa Department of Pediatrics, New York Medical College, Valhalla, NY, USAView further author information
,
Lee Ann Baxter-Loweg Department of Pathology and Laboratory Medicine, Children’s Hospital of Los Angeles, Los Angeles, CA, USAView further author information
&
Mitchell S. Cairoa Department of Pediatrics, New York Medical College, Valhalla, NY, USA;f Department of Pathology, New York Medical College, Valhalla, NY, USA;h Department of Medicine, New York Medical College, Valhalla, NY, USA;i Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA;j Department of Cell Biology and Anatomy, Hematology and Stem Cell Transplantation, Valhalla, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2075-434XView further author information
ORCID Icon show all
Pages 234-237 | Received 08 Mar 2022, Accepted 03 Oct 2022, Published online: 19 Oct 2022

References

  • El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2015;13(2):113–123.
  • Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–393.
  • Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with Central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a children’s oncology group report. Br J Haematol. 2014;167(3):394–401.
  • Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group. Br J Haematol. 2018;182(6):859–869.
  • Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk Central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–2743.
  • Harris RE, Termuhlen AM, Smith LM, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of children’s oncology group study A5962. Biol Blood Marrow Transplant. 2011;17(2):249–258.
  • Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29(2):448–455.
  • Bouabdallah K, Furst S, Asselineau J, et al. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas. Ann Oncol. 2015;26(1):193–198.
  • Cooney-Qualter E, Krailo M, Angiolillo A, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin’s lymphoma: a children’s oncology group study. Clin Cancer Res. 2007;13(18):5652s–5660s.
  • Geyer MB, Jacobson JS, Freedman J, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol. 2011;155(2):218–234.
  • Bhatia M, Militano O, Jin Z, et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010;16(3):333–343.
  • Osunkwo I, Bessmertny O, Harrison L, et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant. 2004;10(4):246–258.
  • Gross TG, Hale GA, He W, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223–230.
  • Cairo MS, Beishuizen A. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. Br J Haematol. 2019;185(6):1021–1042.
  • Chu Y, Gardenswartz A, Termuhlen AM, et al. Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. Br J Haematol. 2019;185(6):1055–1070.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.